Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms [125I]-Osimertinib, [125I]I-osimertinib, EGFR inhibitors (Kanazawa University) |
Target |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 21 L858R mutation inhibitors, SPECT(Single-photon emission-computed tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC28H32IN7O2 |
InChIKeyZTAKGYMAZWGNME-FRTDBYGKSA-N |
CAS Registry2304375-49-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | JP | 11 Jan 2022 |